News2019-09-25T15:29:32-07:00

News

6January 2021

New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Research, Treatments|

*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung cancer.This trial covers travel expenses as well. Any questions can be directed to Dr. Anish Thomas at: Anish.Thomas@nci.gov. (In

6January 2021

Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC

Research, Treatments|

*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 18 mutations, according to interim data from the phase 2 SUMMIT trial.1 Results demonstrated that among 10 evaluable patients

6January 2021

Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer

Research, Treatments|

*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK are now established actionable drivers of oncogenesis, made evident by the availability of FDA-approved and guidelines-indicated therapies for each

6January 2021

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC

Research, Treatments|

*November 2020* Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene addicted tumor. In these patients, despite the clear benefits

6January 2021

Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC

Research, Treatments|

*November 2020* The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such

6January 2021

Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer

Uncategorized|

*November 2020* Communities sharing particular types of the disease are helping steer research towards better therapies. Patient advocates often want immediate results but this can be at odds with the slow pace of scientific investigation. Yet clinicians and scientists

6January 2021

New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer

Research, Treatments|

*September 2020* New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell

6January 2021

Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC

Research, Treatments|

*October 2020* Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD,

6January 2021

ASCO Lung Cancer Roundtable – NSCLC – The SINDAS Trial: Addition of SBRT to a Systemic TKI for EGFR

Research, Treatments|

*October 2020*  The GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies

6January 2021

Targeted Radiation Wins for Treating ‘Numerous’ Brain Metastases 

Research, Treatments|

*October 2020* — Similar survival and less cognitive decline compared with conventional WBRT Stereotactic radiosurgery (SRS) for cancer patients with four to 15 brain metastases staved off cognitive decline better than conventional whole-brain radiation therapy (WBRT), while yielding similar

16October 2020

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

Research, Treatments|

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar

16October 2020

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

Research, Treatments|

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1

16October 2020

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

Research, Treatments|

*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival. Read more.

16October 2020

Dr. Pennell on the Evolution of Targeting HER2 in Lung Cancer

Research, Treatments|

*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses the evolution of targeting HER2 in lung cancer. Watch the video.

16October 2020

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

Research, Treatments|

*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment for patient with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 (METex14) skipping mutation identified via

16October 2020

FDA Grants Priority Review to Trilaciclib in Chemotherapy-Treated Small Cell Lung Cancer

Research, Treatments|

*August 2020* The FDA has granted Priority Review to the New Drug Application (NDA) for trilaciclib (G1T28) for the treatment of patients with small cell lung cancer (SCLC) who are receiving chemotherapy, G1 Therapeutics announced in a press release.

16October 2020

Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment

Research, Treatments|

*August 2020* Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases. Watch video here.

16October 2020

Homing in on Brain Mets’ Distinct Alterations Offers Hope for Precision Medicine Approach

Research, Treatments|

*August 2020* "Brain metastases harbor distinct clinically actionable genetic alterations compared to their primary tumors and extracranial sites." The use of targeted therapies directed at genetic alterations specific to brain metastases is emerging as a viable precision medicine approach

16October 2020

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

Research, Treatments|

*August 2020* Research into mutations in the gene encoding the epidermal growth factor receptor (EGFR) protein has revolutionized non–small cell lung cancer (NSCLC) treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

18September 2020

Knockdown of IKKβ Inhibits Tumor Development in a Leptomeningeal Metastasis Mouse Model and Proliferation of Lung Cancer Cells

Research, Treatments|

*July 2020* Leptomeningeal metastasis (LM) is a devastating, late-stage complication of various solid tumors and is characterized by the diffuse dissemination of malignant tumor cells into the cerebrospinal fluid (CSF) and leptomeninges. Metastasis to this fluid-filled space can quickly spread

18September 2020

Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series

Research, Treatments|

*July 2020* While individualized oncologic treatments are becoming a common practice, it is necessary to evaluate brain metastases (BM) management in a homogeneous primitive population. In patients with a limited number of BM from NSCLC, SRT is an effective

18September 2020

Treatment Landscape Expands for EGFR-Mutated Non–Small Cell Lung Cancer

Research, Treatments|

*July 2020* In an interview with Targeted Oncology, Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, and first director of Clinical Cancer Genetics and professor

18September 2020

Capmatinib Approved in Japan for METex14-Altered Advanced NSCLC

Research, Treatments|

*June 2020* Note: Capmatinib was approved by the FDA in May 2020 for MET exon 14 skipping mutation. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved capmatinib (Tabrecta; formerly INC280) for patients with MET exon 14 skipping (METex14) mutation–positive advanced and/or

12June 2020

Almonertinib Induces Response in EGFR T790M-Positive NSCLC With CNS Metastases

Research, Treatments|

*May 2020* The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile. Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small

8April 2020

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

Research, Treatments|

*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to

8April 2020

Cause of Resistance to 3rd-Gen EGFR-TKIs Varied in T790M-Mutated NSCLC

Research, Treatments|

*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small cell lung cancer (NSCLC) revealed that resistance is associated with diverse pathways. The retrospective study looked at the genomic

8April 2020

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer

Research, Treatments|

*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth

1April 2020

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Research, Treatments|

*January 2020* Among 62 patients who met eligibility critieria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line osimertinib cases and 14% of later-line cases. Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic

4March 2020

Scientists link common immune cell to failure of checkpoint inhibitors in lung cancer

Research, Treatments|

*December 2019* Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and—just as important—who they aren't. Results from a new study published Dec. 19 in

4March 2020

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Research, Treatments|

*January 2020* Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s

4March 2020

FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC

Research, Treatments|

*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva)

18January 2020

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

Research, Treatments|

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib

18January 2020

Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC

Research, Treatments|

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the

18January 2020

Osimertinib promising for EGFR-mutant NSCLC with leptomeningeal metastases

Research, Treatments|

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and

18January 2020

Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers

Funding, Research|

*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center

20December 2019

Project PRIORITY: Why it matters to the EGFR-positive lung cancer community

Advocacy, Coping With Cancer, Research|

*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project

8November 2019

Analyzing Best Practices for Targeting EGFR Resistance Mutations in EGFR+ NSCLC

Research, Treatments|

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is

25September 2019

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Research, Treatments|

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often

12August 2019

In Depth Overview of Tyrosine Kinase Inhibitor Treatment of EGFR+ Lung Cancer

Research, Treatments|

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These

12August 2019

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

Research|

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several

18June 2019

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

Research, Treatments|

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had

17March 2019

Deep Dive: Afatinib+Cetuximab for T790M Neg Patients With Acquired Resistance

Research, Treatments|

*March 2019*  This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to

14March 2019

Novel and Innovative Approach to Monitoring Disease Progression in Cancer on Horizon  

Research, Treatments|

*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet

3February 2019

A cancer researcher reflects on the evolution of lung cancer therapies

Research, Treatments|

*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons.   When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer

3February 2019

Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC

Research, Treatments|

*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from

5January 2019

OncTalk 2018 – Local Therapies for Metastatic Lung Cancer – Who, What, Why, When and How?

Research, Treatments|

*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies

22November 2018

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

Research, Treatments|

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived

22November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Research, Treatments|

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between

18June 2018

Bring Hope Home

Research|

June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the

Living with EGFR

Supporting Research

Finding Hope

Join Us.

Do you (or a loved one) have EGFR-positive lung cancer? Your voice matters! By participating in this survey, YOU could help shape EGFR-positive lung cancer treatment development and future research, ensuring that they address what is most important to the EGFR-positive lung cancer community.
Go to Top